Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NDA Filing Slowdown Continues; FDA Has Received 16 NMEs In FY 2002

Executive Summary

FDA has received only 16 NDA submissions for new molecular entities thus far in fiscal 2002

You may also be interested in...



FDA Wants To Help You Develop Drugs

The agency’s report on innovative drug approvals in FY 2012 documents the successful performance metrics for the 35 novel medicines, including first-cycle review rates and on-time user fee targets, but it notes that a larger problem lies in early stages of drug discovery and development – and it thinks it can help.

Drug Approvals Will Be Down “Significantly” In ’05, FDA’s Gottlieb Predicts

The number of new molecular entities approved by FDA in 2005 will be significantly fewer than in recent years, Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb predicted

Drug Approvals Will Be Down “Significantly” In ’05, FDA’s Gottlieb Predicts

The number of new molecular entities approved by FDA in 2005 will be significantly fewer than in recent years, Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb predicted

Related Content

UsernamePublicRestriction

Register

PS040478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel